Blood Res.  2014 Jun;49(2):85-94. 10.5045/br.2014.49.2.85.

Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants

• Nakashima
• Rogers HJ

• KMID: 2172803
• DOI: http://doi.org/10.5045/br.2014.49.2.85

Abstract

Hypercoagulability can result from a variety of inherited and, more commonly, acquired conditions. Testing for the underlying cause of thrombosis in a patient is complicated both by the number and variety of clinical conditions that can cause hypercoagulability as well as the many potential assay interferences. Using an algorithmic approach to hypercoagulability testing provides the ability to tailor assay selection to the clinical scenario. It also reduces the number of unnecessary tests performed, saving cost and time, and preventing potential false results. New oral anticoagulants are powerful tools for managing hypercoagulable patients; however, their use introduces new challenges in terms of test interpretation and therapeutic monitoring. The coagulation laboratory plays an essential role in testing for and treating hypercoagulable states. The input of laboratory professionals is necessary to guide appropriate testing and synthesize interpretation of results.

Keyword

Hypercoagulability; Algorithmic approach; Antiphospholipid syndrome; Direct oral anticoagulant; Venous thromboembolism

MeSH Terms

Anticoagulants*
Antiphospholipid Syndrome
Humans
Thrombophilia
Thrombosis
Venous Thromboembolism
Anticoagulants

Figure

• 

  Fig. 1 Comprehensive hypercoagulability testing panel using a diagnostic algorithm. Abbreviations: aPTT, activated partial thromboplastin time; B2GP1, beta2 glycoprotein 1; CRP, C-reactive protein; DRVVT, dilute Russell's Viper Venom test; MTHFR, methylenetetrahydrofolate reductase; PL, phospholipid; PNP, platelet neutralization procedure; PT, prothrombin time; SNP, single nucleotide polymorphism.

Reference

1. Olson JD, Eby C. Arterial and venous thrombosis in adults. In : Kottke-Marchant K, editor. An algorithmic approach to hemostasis testing. 1st ed. Northfield, IL: College of American Pathologists;2008. p. 239–266.

2. Margetic S. Diagnostic algorithm for thrombophilia screening. Clin Chem Lab Med. 2010; 48(Suppl 1):S27–S39. PMID: 21054193.

3. Kottke-Marchant K. Laboratory diagnosis of hemorrhagic and thrombotic disorders. Hematol Oncol Clin North Am. 1994; 8:809–853. PMID: 7961292.

4. Khor B, Van Cott EM. Laboratory evaluation of hypercoagulability. Clin Lab Med. 2009; 29:339–366. PMID: 19665682.

5. Heit JA. Thrombophilia: common questions on laboratory assessment and management. Hematology Am Soc Hematol Educ Program. 2007; 127–135. PMID: 18024620.

6. Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol. 2010; 149:209–220. PMID: 20128794.

7. Eby C. Laboratory diagnosis of inherited thrombophilia. In : Kottke-Marchant K, editor. An algorithmic approach to hemostasis testing. 1st ed. Northfield, IL: College of American Pathologists;2008. p. 267–277.

8. Middeldorp S. Evidence-based approach to thrombophilia testing. J Thromb Thrombolysis. 2011; 31:275–281. PMID: 21340752.

9. Van Cott EM, Eby C. Antiphospholipid antibodies. In : Kottke-Marchant K, editor. An algorithmic approach to hemostasis testing. 1st ed. Northfield, IL: College of American Pathologists;2008. p. 295–304.

10. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4:295–306. PMID: 16420554.

11. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009; 7:1737–1740. PMID: 19624461.

12. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med. 1996; 100:530–536. PMID: 8644765.

13. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995; 74:1185–1190. PMID: 8560433.

14. Reber G, de Moerloose P. Anti-beta2-glycoprotein I antibodies-when and how should they be measured? Thromb Res. 2004; 114:527–531. PMID: 15507287.

15. Nichols WL, Kottke-Marchant K, Ledford-Kraemer MR, Homburger HA, Cardel LK. Lupus anticoagulants, antiphospholipid antibodies, and antiphospholipid syndrome. In : Kottke-Marchant K, Davis BH, editors. Laboratory hematology practice. West Sussex, UK: Wiley-Blackwell Publishing ltd;2012. p. 509–525.

16. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012; 157:47–58. PMID: 22313321.

17. Ledford-Kraemer MR, Moore GW, Bottenus R, editors. Laboratory testing for the lupus anticoagulant; Approved guideline. CLSI document H60. Wayne, PA: Clinical and Laboratory Standards Institute;2014.

18. Yohe S, Olson J. Thrombophilia: assays and interpretation. In : Kottke-Marchant K, Davis BH, editors. Laboratory hematology practice. West Sussex, UK: Wiley-Blackwell Publishing ltd;2012. p. 492–508.

19. Moffat KA, Ledford-Kraemer MR, Plumhoff EA, et al. Are laboratories following published recommendations for lupus anticoagulant testing? An international evaluation of practices. Thromb Haemost. 2009; 101:178–184. PMID: 19132206.

20. Triplett DA. Antiphospholipid antibodies. Arch Pathol Lab Med. 2002; 126:1424–1429. PMID: 12421152.

21. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood. 2003; 102:2717–2723. PMID: 12816875.

22. Marai I, Gilburd B, Blank M, Shoenfeld Y. Anti-cardiolipin and anti-beta2-glycoprotein I (beta2GP-I) antibody assays as screening for anti-phospholipid syndrome. Hum Antibodies. 2003; 12:57–62. PMID: 14646033.

23. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995; 85:1504–1508. PMID: 7888671.

24. Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 1997; 89:397–402. PMID: 9002940.

25. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997; 277:1305–1307. PMID: 9109469.

26. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet. 1994; 343:1361–1362. PMID: 7910348.

27. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood. 1998; 91:1135–1139. PMID: 9454741.

28. Franco RF, Elion J, Tavella MH, Santos SE, Zago MA. The prevalence of factor V Arg306-->Thr (factor V Cambridge) and factor V Arg306-->Gly mutations in different human populations. Thromb Haemost. 1999; 81:312–313. PMID: 10064012.

29. Norstrom E, Thorelli E, Dahlback B. Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood. 2002; 100:524–530. PMID: 12091344.

30. Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med. 2002; 126:1304–1318. PMID: 12421138.

31. Ledford M, Friedman KD, Hessner MJ, Moehlenkamp C, Williams TM, Larson RS. A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescence resonance energy transfer (FRET) assay. J Mol Diagn. 2000; 2:97–104. PMID: 11272895.

32. Murugesan G, Jans S, Han JY. Single nucleotide polymorphisms in molecular diagnostics. In : Kottke-Marchant K, Davis BH, editors. Laboratory hematology practice. West Sussex, UK: Wiley-Blackwell Publishing ltd;2012. p. 168–180.

33. McGlennen RC, Key NS. Clinical and laboratory management of the prothrombin G20210A mutation. Arch Pathol Lab Med. 2002; 126:1319–1325. PMID: 12421139.

34. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998; 79:706–708. PMID: 9569177.

35. Ballard RB, Marques MB. Pathology consultation on the laboratory evaluation of thrombophilia: when, how, and why. Am J Clin Pathol. 2012; 137:553–560. PMID: 22431530.

36. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996; 88:3698–3703. PMID: 8916933.

37. Khor B, Van Cott EM. Laboratory tests for protein C deficiency. Am J Hematol. 2010; 85:440–442. PMID: 20309856.

38. Van Cott EM, Laposata M, Prins MH. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med. 2002; 126:1281–1295. PMID: 12421136.

39. Maurissen LF, Thomassen MC, Nicolaes GA, et al. Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation. Blood. 2008; 111:3034–3041. PMID: 18160668.

40. Rosing J, Maurissen LF, Tchaikovski SN, Tans G, Hackeng TM. Protein S is a cofactor for tissue factor pathway inhibitor. Thromb Res. 2008; 122:S60–S63. PMID: 18691502.

41. Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol. 2001; 113:636–641. PMID: 11380449.

42. Aillaud MF, Pouymayou K, Brunet D, et al. New direct assay of free protein S antigen applied to diagnosis of protein S deficiency. Thromb Haemost. 1996; 75:283–285. PMID: 8815577.

43. Castoldi E, Hackeng TM. Regulation of coagulation by protein S. Curr Opin Hematol. 2008; 15:529–536. PMID: 18695379.

44. Ten Kate MK, Platteel M, Mulder R, et al. PROS1 analysis in 87 pedigrees with hereditary protein S deficiency demonstrates striking genotype-phenotype associations. Hum Mutat. 2008; 29:939–947. PMID: 18435454.

45. Mackie I, Cooper P, Lawrie A, Kitchen S, Gray E, Laffan M. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int J Lab Hematol. 2013; 35:1–13. PMID: 22978493.

46. Vossen CY, Conard J, Fontcuberta J, et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost. 2004; 2:1526–1532. PMID: 15333025.

47. Rogers HJ, Kottke-Marchant K. Antithrombin deficiency. In : Gulati G, Filicko-O'Hara J, Krause JR, editors. Case studies in hematology and coagulation. . Chicago, IL: American Society for Clinical Pathology Press;2012. p. 416–418.

48. Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med. 2002; 126:1326–1336. PMID: 12421140.

49. Picard V, Nowak-Gottl U, Biron-Andreani C, et al. Molecular bases of antithrombin deficiency: twenty-two novel mutations in the antithrombin gene. Hum Mutat. 2006; 27:600. PMID: 16705712.

50. Khor B, Van Cott EM. Laboratory tests for antithrombin deficiency. Am J Hematol. 2010; 85:947–950. PMID: 21108326.

51. Rao AK, Niewiarowski S, Guzzo J, Day HJ. Antithrombin III levels during heparin therapy. Thromb Res. 1981; 24:181–186. PMID: 6800057.

52. Guba SC, Fonseca V, Fink LM. Hyperhomocysteinemia and thrombosis. Semin Thromb Hemost. 1999; 25:291–309. PMID: 10443960.

53. Eldibany MM, Caprini JA. Hyperhomocysteinemia and thrombosis: an overview. Arch Pathol Lab Med. 2007; 131:872–884. PMID: 17550314.

54. Ray JG, Shmorgun D, Chan WS. Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb. 2002; 32:51–58. PMID: 12214149.

55. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005; 3:292–299. PMID: 15670035.

56. Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013; 15:153–156. PMID: 23288205.

57. O'Donnell J, Mumford AD, Manning RA, Laffan M. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost. 2000; 83:10–13. PMID: 10669146.

58. Oger E, Lacut K, Van Dreden P, et al. High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderly. Haematologica. 2003; 88:465–469. PMID: 12681975.

59. Ota S, Yamada N, Ogihara Y, et al. High plasma level of factor VIII: an important risk factor for venous thromboembolism. Circ J. 2011; 75:1472–1475. PMID: 21498909.

60. Jenkins PV, Rawley O, Smith OP, O'Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol. 2012; 157:653–663. PMID: 22530883.

61. Kraaijenhagen RA, in't Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 2000; 83:5–9. PMID: 10669145.

62. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000; 343:457–462. PMID: 10950667.

63. Benjaber K, Constans J, Cougnard A, Salmi LR. High levels of factor VIIIc and risk of venous thrombosis: critical analysis of case-control studies. Rev Med Interne. 2003; 24:366–371. PMID: 12814825.

64. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost. 1995; 73:151–161. PMID: 7740487.

65. Cunningham MT, Brandt JT, Laposata M, Olson JD. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med. 2002; 126:499–505. PMID: 11900586.

66. Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med. 2002; 126:1387–1390. PMID: 12421146.

67. Verhovsek M, Moffat KA, Hayward CP. Laboratory testing for fibrinogen abnormalities. Am J Hematol. 2008; 83:928–931. PMID: 18951466.

68. Mani H, Kasper A, Lindhoff-Last E. Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. J Thromb Thrombolysis. 2013; 36:187–194. PMID: 23512159.

69. Eby C. Novel anticoagulants and laboratory testing. Int J Lab Hematol. 2013; 35:262–268. PMID: 23590653.

70. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139–1151. PMID: 19717844.

71. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981–992. PMID: 21870978.

72. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883–891. PMID: 21830957.

73. Steiner T, Bohm M, Dichgans M, et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol. 2013; 102:399–412. PMID: 23669868.

74. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013; 11:756–760.

75. Harenberg J, Marx S, Weiss C, Kramer R, Samama M, Schulman S. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost. 2012; 10:1433–1436. PMID: 22947062.

76. Harenberg J, Du S, Weiss C, Kramer R, Hoppensteadt D, Walenga J. Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH. J Thromb Haemost. 2014; 12:801–804. PMID: 24597497.

77. Mani H. Interpretation of coagulation test results under direct oral anticoagulants. Int J Lab Hematol. 2014; 36:261–268. PMID: 24750672.

78. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb. 2003; 33:173–183. PMID: 15583446.